Cargando…
Immunoinformatics Approach to Design a Novel Subunit Vaccine Against Visceral Leishmaniasis
Visceral leishmaniasis (VL) infection is mostly caused by Leishmania donovani and affects countries worldwide. Despite the need for a safe and effective vaccine against leishmaniasis due to the increased drug resistance, however, no vaccine has yet been licensed for clinical use. This study revolves...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8675112/ https://www.ncbi.nlm.nih.gov/pubmed/34931120 http://dx.doi.org/10.1007/s10989-021-10344-3 |
_version_ | 1784615812308402176 |
---|---|
author | Lari, Alireza Lari, Niloofar Biabangard, Atefeh |
author_facet | Lari, Alireza Lari, Niloofar Biabangard, Atefeh |
author_sort | Lari, Alireza |
collection | PubMed |
description | Visceral leishmaniasis (VL) infection is mostly caused by Leishmania donovani and affects countries worldwide. Despite the need for a safe and effective vaccine against leishmaniasis due to the increased drug resistance, however, no vaccine has yet been licensed for clinical use. This study revolves around the immunoinformatics approach to design a multi-epitope vaccine against VL infection. In this case, the proteome of L. donovani has been investigated, and three host non-homologous and antigenic extracellular secretory proteins have been identified as potential vaccine candidates with low transmembrane helices (≤ 1). The multi-epitope subunit vaccine construct consists of T-cell (cytotoxic T-lymphocyte (CTL) and helper T-lymphocyte (HTL)) epitopes accompanied by appropriate adjuvant and linkers. A 372-amino acid vaccine construct has been established with specific characteristics, such as soluble, stable, antigenic, non-allergenic, non-toxic, and non-host homologous. Besides, the tertiary structure of the designed vaccine was modeled and validated. Also, the stability and affinity of the vaccine- TLR4 complex were confirmed by using molecular docking and molecular dynamics (MD) simulation. In addition, in silico immunization assay showed the efficiency of this candidate vaccine to stimulate an effective immune response. Furthermore, the refined vaccine was optimized and cloned in the pET28a (+) vector, and its successful expression was confirmed virtually. However, the experimental validation is required to verify the multi-epitope vaccine efficacy against VL infection. |
format | Online Article Text |
id | pubmed-8675112 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-86751122021-12-16 Immunoinformatics Approach to Design a Novel Subunit Vaccine Against Visceral Leishmaniasis Lari, Alireza Lari, Niloofar Biabangard, Atefeh Int J Pept Res Ther Article Visceral leishmaniasis (VL) infection is mostly caused by Leishmania donovani and affects countries worldwide. Despite the need for a safe and effective vaccine against leishmaniasis due to the increased drug resistance, however, no vaccine has yet been licensed for clinical use. This study revolves around the immunoinformatics approach to design a multi-epitope vaccine against VL infection. In this case, the proteome of L. donovani has been investigated, and three host non-homologous and antigenic extracellular secretory proteins have been identified as potential vaccine candidates with low transmembrane helices (≤ 1). The multi-epitope subunit vaccine construct consists of T-cell (cytotoxic T-lymphocyte (CTL) and helper T-lymphocyte (HTL)) epitopes accompanied by appropriate adjuvant and linkers. A 372-amino acid vaccine construct has been established with specific characteristics, such as soluble, stable, antigenic, non-allergenic, non-toxic, and non-host homologous. Besides, the tertiary structure of the designed vaccine was modeled and validated. Also, the stability and affinity of the vaccine- TLR4 complex were confirmed by using molecular docking and molecular dynamics (MD) simulation. In addition, in silico immunization assay showed the efficiency of this candidate vaccine to stimulate an effective immune response. Furthermore, the refined vaccine was optimized and cloned in the pET28a (+) vector, and its successful expression was confirmed virtually. However, the experimental validation is required to verify the multi-epitope vaccine efficacy against VL infection. Springer Netherlands 2021-12-16 2022 /pmc/articles/PMC8675112/ /pubmed/34931120 http://dx.doi.org/10.1007/s10989-021-10344-3 Text en © The Author(s), under exclusive licence to Springer Nature B.V. 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Article Lari, Alireza Lari, Niloofar Biabangard, Atefeh Immunoinformatics Approach to Design a Novel Subunit Vaccine Against Visceral Leishmaniasis |
title | Immunoinformatics Approach to Design a Novel Subunit Vaccine Against Visceral Leishmaniasis |
title_full | Immunoinformatics Approach to Design a Novel Subunit Vaccine Against Visceral Leishmaniasis |
title_fullStr | Immunoinformatics Approach to Design a Novel Subunit Vaccine Against Visceral Leishmaniasis |
title_full_unstemmed | Immunoinformatics Approach to Design a Novel Subunit Vaccine Against Visceral Leishmaniasis |
title_short | Immunoinformatics Approach to Design a Novel Subunit Vaccine Against Visceral Leishmaniasis |
title_sort | immunoinformatics approach to design a novel subunit vaccine against visceral leishmaniasis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8675112/ https://www.ncbi.nlm.nih.gov/pubmed/34931120 http://dx.doi.org/10.1007/s10989-021-10344-3 |
work_keys_str_mv | AT larialireza immunoinformaticsapproachtodesignanovelsubunitvaccineagainstvisceralleishmaniasis AT lariniloofar immunoinformaticsapproachtodesignanovelsubunitvaccineagainstvisceralleishmaniasis AT biabangardatefeh immunoinformaticsapproachtodesignanovelsubunitvaccineagainstvisceralleishmaniasis |